SUPBIO
Changing the Future of HIV Care with a DNA-Based Diagnostic Breakthrough

In the global fight against HIV, one of the greatest clinical challenges is detecting the virus. While standard diagnostic tests, focused on PCR viral RNA or antigens/ antibodies, excel at identifying active infection, they fall dangerously short when it comes to uncovering HIV reservoirs—dormant cells where the virus hides in its DNA into the host cells. These reservoirs evade even the most aggressive antiretroviral therapy (ART) and remain the silent threat behind viral rebound and ART failure.

Without visibility into these hidden strongholds, clinicians are left in the dark. A patient may show undetectable viral loads, yet still harbor the seeds of resurgence. A diagnostic blind spot like this undermines efforts toward a functional cure and limits how the success of ART treatment is truly measured.

SUPBIO’s HIV-1 DNA Quantitative Detection Kit delivers the breakthrough that the HIV Diagnostics field has long awaited.

By directly quantifying total HIV-1 DNA, it provides an unprecedented window into early infection, the viral reservoir, transforming how disease progression is tracked, how ART treatment is evaluated and how care is personalized for long-term outcomes.

This capability is nothing short of pivotal—as it empowers clinicians to track the size of the HIV reservoir over the entire course of infection, offering visibility into how effectively ART is suppressing the virus at its genomic source. By directly measuring the hidden viral burden, SUPBIO’s kit equips physicians with data they have never had before, enabling more informed, precision-driven treatment decisions. Clinicians can now optimize the timing of therapy initiation, modification, or de-escalation, thereby reducing unnecessary exposure to the long-term side effects of ART while maintaining viral control.

For the research community, this precision unlocks a consistent, reproducible method for evaluating experimental therapies aimed at reservoir eradication, closing one of the most persistent measurement gaps in HIV cure research.

More than a diagnostic tool, SUPBIO’s kit also reimagines how ART response is monitored in real time. By enabling longitudinal comparison of HIV-1 DNA and RNA levels, it reveals subtle shifts in reservoir decay and flags emerging risks. Persistent HIV-1 DNA becomes a powerful early indicator—not just of therapeutic resistance, but of early diagnosis of infection, potential immune dysfunction or impending virologic rebound. This transforms treatment from reactive crisis management to proactive, data-guided care.

“We are bridging a long-standing gap in the HIV diagnostics arsenal, delivering the insight today’s clinicians need, and laying the foundation for how tomorrow’s HIV care will be delivered,” says Tuofu Zhu, president of SUPBIO.

The Founding Mission

Challenging convention has always defined Tuofu Zhu’s approach. In 2010, when he surveyed the in vitro diagnostics (IVD) landscape, he saw a critical flaw that most diagnostic tools offered static snapshots that are capable of confirming disease presence, but blind to its trajectory or response to treatment. He envisioned a new era of diagnostics—one that could detect diseases earlier, track their progression in real-time and actively inform therapeutic decisions.

That vision became the cornerstone of SUPBIO’s HIV-1 DNA Quantitative Detection Kit. Rather than simply identifying infection, Zhu set out to solve the deeper problem of diagnostic invisibility, creating a tool that reveals the true burden of HIV reservoir, measures treatment efficacy at the genomic level and empowers clinicians to act with greater accuracy, speed and confidence. In bridging the gap between early detection and cure, Zhu redefined what diagnostics can—and should—do in the fight against HIV.

Any Setting, Total Compatibility

Usability is at the heart of SUPBIO’s HIV-1 DNA Quantitative Detection Kit. Engineered for flexibility, the kit integrates effortlessly into clinical workflows, whether in hospitals, CDC laboratories, public health facilities or remote collection environments. For high-risk individuals and under-served populations, SUPBIO offers an at-home collection option that includes all necessary materials for a simple blood sample. The specimen is then securely shipped to certified labs, bridging the divide between medical-grade diagnostics and community-accessible testing, without compromising accuracy or clinical oversight.

Universal compatibility with standard PCR analyzers further accelerates adoption. Healthcare providers can incorporate the test seamlessly, without the need to invest in new equipment—a critical advantage in resource-constrained settings. An integrated internal control enhances reliability by concurrently verifying both viral and human gene targets in a single reaction. This reduces the risk of false negatives, minimizes the need for retesting and increases lab throughput and confidence in results.

Beyond convenience, the kit addresses critical clinical gaps. It enables early infant diagnosis, overcoming the limitations of antibody-based tests affected by maternal antibodies. In pre- and post-exposure prophylaxis (PrEP/PEP) scenarios, it facilitates ultra-early detection, identifying HIV even before RNA or antigens/antibodies are present. This empowers clinicians to intervene more quickly, reduce transmission risk and make safer treatment decisions when timing is critical.

Backed by 100 Studies, Built for the World

SUPBIO’s HIV-1 DNA Quantitative Detection Kit has not only undergone rigorous clinical validation, it’s redefining diagnostic standards on a national and global scale. Cited in over 100 peer-reviewed publications, the kit’s effectiveness has been rigorously confirmed across diverse patient populations and care environments. This robust body of evidence is the result of more than 80 multi-center studies, led by over 100 top-tier clinical and research teams from leading hospitals, diagnostic centers and academic institutions. Collectively, their work has solidified the kit’s indispensable role in both diagnosis and therapeutic decision-making.

Its clinical relevance has now been formally recognized in six national guidelines and expert consensus statements, underscoring its emergence as a gold standard in modern HIV diagnostics. In China, insights from these studies have directly shaped national testing protocols—currently being revised to further institutionalize the kit’s role across hospitals, public health agencies, and laboratories.

Through strategic partnerships with chief physicians and senior clinicians, SUPBIO has embedded the kit into routine clinical practice across major medical systems. Now, with expansion underway across Asia and Africa, the company is unlocking access in regions where early, accurate HIV detection remains a critical unmet need.

More than a scientific breakthrough, SUPBIO’s advancement is a rallying point for global health equity; it’s a call to align technology, policy and care delivery in pursuit of a world free from the grip of the HIV epidemic, once and for all.